| 000 | 03620naa a22004697i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-MLS-040 | ||
| 003 | local | ||
| 005 | 20261005174904.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2023 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1038/s41392-023-01521-5 _2doi |
|
| 035 | _a(local)EuropePMC:PMC10435569 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aLu Tang _eauthor. |
|
| 245 | 1 | 0 |
_aImmunotherapy in hematologic malignancies: achievements, challenges and future prospects. / _cLu Tang; Zhongpei Huang; Heng Mei [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bNature Publishing Group, _c2023. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aThe immune-cell origin of hematologic malignancies provides a unique avenue for the understanding of both the mechanisms of immune responsiveness and immune escape, which has accelerated the progress of immunotherapy. Several categories of immunotherapies have been developed and are being further evaluated in clinical trials for the treatment of blood cancers, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies. These immunotherapies have shown the potential to induce long-term remission in refractory or relapsed patients and have led to a paradigm shift in cancer treatment with great clinical success. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. To provide clinicians with timely information on these revolutionary therapeutic approaches, the comprehensive review provides historical perspectives on the applications and clinical considerations of the immunotherapy. Here, we first outline the recent advances that have been made in the understanding of the various categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects and toxicity management and then provide novel insights into challenges and future directions. | |
| 540 |
_aCreative Commons Attribution. See the linked licence for the applicable terms. _uhttps://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Medical Laboratory Science. | ||
| 653 | _aB. Sc. Medical Laboratory Science | ||
| 653 | _aUMUN open access collection | ||
| 653 | _ahematology | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aZhongpei Huang _eauthor. |
|
| 700 | 0 |
_aHeng Mei _eauthor. |
|
| 700 | 0 |
_aYu Hu _eauthor. |
|
| 773 | 0 |
_tSignal transduction and targeted therapy _gVol. 8, no. 1, (2023), pages/article 306 _x2095-9907 |
|
| 856 | 4 | 0 |
_uhttps://europepmc.org/articles/PMC10435569 _yRead open-access publication _zOpen access. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from Europe PMC metadata. _g20261005 _khttps://europepmc.org/articles/PMC10435569 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1182 _d1182 |
||